problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl13198problendo-13198Research ArticleРепродуктивная эндокринологияReproductive EndocrinologyРоль эстриола в лечении атрофии слизистой оболочки нижних отделов мочеполового тракта в постменопаузеThe role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal womenhttps://orcid.org/0000-0001-8425-0020АндрееваЕ. Н.AndreevaE. N.

Андреева Елена Николаевна - д.м.н.

117036, Москва, ул. Дмитрия Ульянова, д. 11

SPIN-код: 1239-2937

Elena N. Andreeva - MD, PhD, DSc

11 Dm. Ulyanov str., Moscow, 117036

SPIN-код: 1239-2937

endogin@mail.ruhttps://orcid.org/0000-0001-7177-0254ШереметьеваЕ. В.SheremetyevaE. V.

Шереметьева Екатерина Викторовна - к.м.н., вед.научн. сотрудник Отделения эндокринной гинекологии Института репродуктивной медицины

117036, Москва, ул. Дмитрия Ульянова, д. 11

SPIN-код: 9413-5136

Ekaterina V. Sheremetyeva - MD, PhD

11 Dm. Ulyanov str., Moscow, 117036

SPIN-код: 9413-5136

s1981k@yandex.ruНациональный медицинский исследовательский центр эндокринологии; Московский медицинский медико-стоматологический университет им. А.И. ЕвдокимоваРоссияEndocrinology Research Centre; Evdokimov Moscow State University of Medicine and DentistryRussian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202220122022686157163Copyright © Андреева Е.Н., Шереметьева Е.В., 20222022Андреева Е.Н., Шереметьева Е.В.Andreeva E.N., Sheremetyeva E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/13198

Исследования последних десятилетий показывают неуклонный рост средней продолжительности жизни человека, и женщины в частности. Всемирная организация здравоохранения прогнозирует к 2030 г. четырехкратное увеличение численности женщин старше 70 лет, при этом многие из них в возрасте после 45 лет могут столкнуться с проблемами климактерического периода. Климактерий является физиологическим состоянием в жизни женщины, в течение которого на фоне возрастных изменений происходят постепенное снижение и выключение функции яичников и прекращение выработки эстрогенов. Генитоуринарный синдром встречается у каждой третьей женщины в этом периоде. Эстриол — основной эстроген, который таргетно решает проблемы, обусловленные эстрогенной недостаточностью: диспареунии, сухости и зуда во влагалище и нижних отделах мочеполового тракта, нарушения мочевыведения, умеренного недержания мочи, а также рецидивирующего вульвовагинита и цистита. Вульвовагинальная дистрофия у женщин старшей возрастной группы — это мультидисциплинарная проблема на стыке гинекологии, урологии и дерматологии, которая может и должна быть решена для предотвращения более тяжелой гинекологической и урологической патологий.

Studies of recent decades show a steady increase in the average life expectancy of a person, and women in particular. The World Health Organization predicts a four-fold increase in the number of women over 70 by 2030, and many of them over the age of 45 may face menopausal problems. Menopause is a physiological state in a woman’s life, during which, against the background of age-related changes, there is a gradual decrease and shutdown of ovarian function and the cessation of estrogen production. Genitourinary syndrome occurs in every third woman in this period. Estriol is the main estrogen that specifically addresses problems associated with estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary incontinence, moderate urinary incontinence, and recurrent vulvovaginitis and cystitis. Vulvovaginal dystrophy in women of the older age group is a multidisciplinary problem at the intersection of gynecology, urology and dermatology, which can and should be solved to prevent more severe gynecological and urological pathologies.

эстриолвульвовагинальная атрофиягенитоуринарный синдромпостменопаузанедержание мочиestriolvulvo-vaginal atrophygenitourinary syndromepostmenopauseurinary incontinenceAndreeva E.N., Sheremet'eva E.V. Psikhicheskie aspekty i narushenie zhirovogo obmena v klimakterii // Akusherstvo i ginekologiya. — 2019. — №9. — S. 165-172.Tkacheva O.N., Runikhina N.K., Kotovskaya Yu.V., i dr. Metodicheskie rekomendatsii «Profilaktika prezhdevremennogo stareniya u zhenshchin». M; 2018.Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279-285. doi: https://doi.org/10.1080/13697130902814751Panay N, Palacios S, Bruyniks N, et al. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124(4):55-61. doi: https://doi.org/10.1016/j.maturitas.2019.03.013Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286-291. doi: https://doi.org/10.1080/13697137.2018.1446930Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508-516. doi: https://doi.org/10.1097/GRF.0000000000000380Vieira-Baptista P, Donders G, Margesson L, et al. Diagnosis and management of vulvodynia in postmenopausal women. Maturitas. 2018;(108):84-94. doi: https://doi.org/10.1016/j.maturitas.2017.11.003Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18(S1):18-22. doi: https://doi.org/10.3109/13697137.2015.1078206Rossiiskoe obshchestvo urologov. Klinicheskie rekomendatsii. Nederzhanie mochi u vzroslykh. M.: MZ RF; 2020.Krychman M, Graham S, Bernick B, et al. The women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425-433. doi: https://doi.org/10.1016/j.jsxm.2017.01.011Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-day impact of vaginal aging questionnaire. Menopause. 2015;22(2):144-154. doi: https://doi.org/10.1097/GME.0000000000000281Angelou K, Grigoriadis T, Diakosavvas M, et al. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020;12(4):e7586. doi: https://doi.org/10.7759/cureus.7586Angelou K, Grigoriadis T, Diakosavvas M, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi: https://doi.org/10.1097/GME.0000000000001609Apolikhina I.A., Yureneva S.V., Malyshkina D.A. Genitourinarnyi menopauzal'nyi sindrom: sovremennye podkhody k diagnostike i lecheniyu // Akusherstvo i ginekologiya. — 2020. — №12. — S. 4-8.Mension E, Alonso I, Castelo-Branco C. Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors – Systematic Review. Maturitas. 2021;143(9):47-58. doi: https://doi.org/10.1016/j.maturitas.2020.08.010Li B, Duan H, Chang Y, Wang S. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. Pharmacol Res. 2021;164(9):105360. doi: https://doi.org/10.1016/j.phrs.2020.105360Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: https://doi.org/10.3109/13697137.2015.1129166Punnonen R, Vilska S, Grönroos M, Rauramo L. The vaginal absorption of oestrogens in postmenopausal women. Maturitas. 1980;2(4):321-326. doi: https://doi.org/10.1016/0378-5122(80)90034-1Reed-Kane D. Natural hormone replacement therapy: What it is and what consumers really want. Int J Pharmaceut Compounding. 2001;5(5):332-335.Khan Ikram Ullah Serra Christophe A. Anton Nicolas Er-Rafik Mériem Blanck C. Schmutz Marc Kraus Isabelle Messaddeq Nadia Sutter Christophe Anton Halina Klymchenko Andrey S. Vandamme Thierry F. Microfluidic conceived Trojan microcarriers for oral delivery of nanoparticles International Journal of Pharmaceutics 2015 06 7 15 493 1-2 10.1016/j.ijpharm.2015.06.028Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharmaceutics. 2012;4(1):1-25. doi: https://doi.org/10.3390/pharmaceutics4010001Anton Nicolas Li Xiang Chau Ta Minh Zhao Minjie Messaddeq Nadia Vandamme Thierry Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery International Journal of Nanomedicine 2011 06 1313 10.2147/ijn.s20353Prilepskaya V.N., Nazarenko E.G. Estriol v terapii razlichnykh ginekologicheskikh zabolevanii // Meditsinskii Sovet. — 2017. — №2. — S. 8-13.Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995;62(1):101-106. doi: https://doi.org/10.1016/0301-2115(95)02170-CAli ES, Mangold C, Peiris AN. Estriol: emerging clinical benefits. Menopause. 2017;24(9):1081-1085. doi: https://doi.org/10.1097/GME.0000000000000855Capobianco G, Donolo E, Borghero G, et al. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2012;285(2):397-403. doi: https://doi.org/10.1007/s00404-011-1955-1Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG An Int J Obstet Gynaecol. 2000;107(8):1029-1034. doi: https://doi.org/10.1111/j.1471-0528.2000.tb10408.xFederal'nyi zakon ot 12.04.2010 N 61-FZ (red. ot 14.07.2022) «Ob obrashchenii lekarstvennykh sredstv». Federal Law of Russian Federation 12.04.2010 N 61-FZ (red. ot 14.07.2022) «Ob obrashchenii lekarstvennykh sredstv» (In Russ.).Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii. Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. M.: MZ RF; 2021.Lumsden MA, Davies M, Sarri G. Diagnosis and Management of Menopause. JAMA Intern Med. 2016;176(8):1205. doi: https://doi.org/10.1001/jamainternmed.2016.2761Vzaimozamenyaemye lekarstvennye preparaty (p. 4 ch. 4 st. 3 Federal'nogo zakona ot 27.12.2019 № 475-FZ, p. 8 postanovleniya Pravitel'stva ot 05.09.2020 № 1360).Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522. doi: https://doi.org/10.3109/13697137.2010.522875Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452-461. doi: https://doi.org/10.1097/GME.0000000000000768Vetuschi A. D'Alfonso A. Sferra R. Zanelli D. Pompili S. Patacchiola F. Gaudio E. Carta G. Changes in muscularis propria of anterior vaginal wall in women with pelvic organ prolapse European Journal of Histochemistry 2016 03 60 1 10.4081/ejh.2016.2604Donders Gilbert G. G. Ruban Kateryna Bellen Gert Grinceviciene Svitrigaile Pharmacotherapy for the treatment of vaginal atrophy Expert Opinion on Pharmacotherapy 2019 03 821 835 20 7 10.1080/14656566.2019.1574752Traish AM, Vignozzi L, Simon JA, et al. Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sex Med Rev. 2018;6(4):558-571. doi: https://doi.org/10.1016/j.sxmr.2018.03.005Pessina MA, Hoyt RF, Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology. 2006;147(1):61-69. doi: https://doi.org/10.1210/en.2005-0870Berman Jennifer R. Almeida Fernando G. Jolin Julie Raz Shlomo Chaudhuri Gautam Gonzalez-Cadavid Nestor F. Correlation of androgen receptors, aromatase, and 5-α reductase in the human vagina with menopausal status Fertility and Sterility 2003 05 925 931 79 4 10.1016/s0015-0282(02)04923-3Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401-2412. doi: https://doi.org/10.1111/jsm.13045Merritt P, Stangl B, Hirshman E, Verbalis J. Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short-term memory in post-menopausal women. Brain Res. 2012;(1483):54-62. doi: https://doi.org/10.1016/j.brainres.2012.09.015Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women. Menopause. 2011;18(1):30-43. doi: https://doi.org/10.1097/gme.0b013e3181e195a6Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii. Vypadenie zhenskikh polovykh organov. M.: MZ RF; 2021.Rossiiskoe obshchestvo urologov. Klinicheskie rekomendatsii. Tsistit u zhenshchin. M.: MZ RF; 2021.Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide Maturitas 2021;148:55-61. Available from: https://emas-online.org/emas-clinical-guides/Griesser Henrik Skonietzki Stefan Fischer Thomas Fielder Karin Suesskind Marija Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol Maturitas 2012 01 360 368 71 4 10.1016/j.maturitas.2011.12.022Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321-330. doi: https://doi.org/10.1080/13697137.2017.1329291Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(11). doi: https://doi.org/10.1002/14651858.CD001500.pub3

The authors declare that there are no conflicts of interest present.